• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
Mad Hedge Fund Trader

Is it Time to Get Back Into Uber?

Tech Letter

I dig it that Uber has larger data sets than anyone else in a world where bigger is better in terms of data.

What they have is ultimately uber valuable in the modern day of data being the new oil.

This advantage is precisely why Uber is able to train an in-house algorithm better than the next guy.

Global reference points are what every company these days lust for.

Matching and routing an incentives marketing engine that is highly personalized is an existential issue for ride-sharing giant Uber.

When you parlay their data edge with possessing op teams on the ground in every single market and understanding of the regulatory marketplace as well, it means per unit, Uber’s overheads are way lighter than competitors.

It all translates into cost of customer acquisition being lower and a higher lifetime value because of the higher frequency accounts that they have with customers.

You could almost say that in this particular industry, it’s a game of who can outdo one another in customer acquisition unit cost.

Beating on cost is a must because Uber has all these unprofitable businesses and when it comes down to it, they are a glorified delivery driving service.

They must acquire to scale out because that’s the only hope they have to become profitable by wielding the economies of scale advantage.

Uber’s Grocery division is off to a great start internationally and at home in the U.S., Instacart is a strong competitor.

So I do believe they face a steep uphill climb to get anywhere near Instacart who has had skin in the game forever.

But when we get into the weeds, Uber’s short-term direction will clearly be driven by the supply of drivers or the lack of them for a reasonable price.

In July, new driver additions on Uber in the U.S. grew 30% month-over-month. That's right, 30% month-over-month even as they pulled back on incentives and improved margins. As investments taper, Uber expect mobility to show strong leverage in the back half.

Management tried to gloss up results but Uber had spent a massive $250m in driver incentive investment in the second quarter, which increased losses at its ride-hail business.

I mentioned at the top that Uber’s model is about low-quality tech married with scale, thus, there’s no way to justify spending $250m in one quarter to find drivers.

The dearth of drivers came about because of incremental government stimulus, lack of child care services, unemployment subsidies, even preventative virus concerns, or simply some drivers just died of corona.

Not only is data the oil for Uber, but in that oil, one massively important input is the cost of acquiring drivers.

For management to be so behind the curve on this one shows a degree of unpreparedness.

Granted, it’s been quite difficult for any tech management to get a hold of the new tech trends post-pandemic, but that’s what they are paid to do.

Shares of Uber have tanked around 30% since mid-February this year speaking volumes to management lack of execution in supplying the volume of drivers.

I know it’s not a simple one-day smash and grab to get drivers.

We are talking about marketing, onboard costs, background checks, vaccinations, promotions, registration process and education.

This isn’t all free.

I would hope that as we approach 2022, those costs become less of a burden.

But it does go to show that for Uber, the honeymoon period is long gone and even the low-hanging fruit area doesn’t exist anymore.

We seem to have entered a phase of chronic underperformance met with a finite period of overperformance the only to shift backwards again and repeat the same cycle over again.

 

As we look at the rest of 2021, the driver acquisition marketplace is unhealthy and wait times are up big causing surge pricing to make Uber a pricy service.

I don’t see that moving significantly down by end of 2021, but this specific headwind will moderate which is good for the stock.  

A little bit more regionally, a bunch of cities, southern cities are actually back to normal and it’s about putting dollars in front of drivers and the top 20 cities, drivers for mobility are making over $40 an active hour, including just earnings and tips as well.

I will tell you - this company has no chance to become profitable if they are doling out a median wage of $40 per hour.

It’s a fool’s game.

Even if you want to get “leaner”, I don’t see where the cost savings will come from unless they want to gut the corporate staff or cut back on the technology.

That’s not to say they will even be able to retain drivers who might get better offers in different industries and never consider driving an Uber again.

I mean honestly, being an Uber driver isn’t exactly a desirable job for most people unless you have no skills or no better options.

Everyone wants to work at home from a desk and computer where they can brew their own coffee and not commute. Being a driver is a job where you are in perpetual commute!

And if less skilled workers are being paid to stay home with an eviction moratorium so they don’t have to pay rent or a mortgage forbearance, so they don’t need to leave home, then it’s gotten so bad that Uber is paying $40 per hour to move the needle.

Regional cities have recovered but driver supply problem is acute in major cities like New York, San Francisco and L.A. with demand continuing to outplay supply and prices and wait times remain above comfort levels.

When this happens, customers stop using your service and for a company that relies on high volume, it couldn’t be more than terrible.

It means Uber doesn’t get paid when people are clamoring for their service.

I just don’t see Uber going into other markets and burning more cash to stay relevant because they are too mature of a company.

They are running out of gunpowder in 2021 and will expect to pump out the profits soon.

To profit means outperformance and Uber hasn’t delivered more than the dead cat bounce of the economy reopening which is a little pitiful.

I made a bullish call earlier this year which was correct at the time but then Uber hit a wall at $65 and has come back down with vengeance.

I can say that at $43 today, the stock will rise if Uber’s management can trim the $40 per hour they are paying drivers today while increasing driver headcount by 30% quarter over quarter.

I believe Uber’s management will be successful at bringing down driver costs.

It’s easy to see how they go down from here, and I do believe that the bad news is priced into Uber shares, and that many of these headwinds were transitory and the outlook will improve moving into 2022.

Even though I forecast the stock going up in the short to midterm, I still believe at some point, the company will need to come to terms with having no cutting-edge technology and no moat around its business model.

That issue has been lying dormant but that doesn’t mean it has gone away.

Just think about it, if Amazon or Google wanted to do what Uber does, they could figure it out in months, but they don’t see any value in this profit model.

Uber is definitely on the clock and that’s not a good thing for their management.

 

uber management

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-08-06 15:02:102021-08-15 21:57:15Is it Time to Get Back Into Uber?
Mad Hedge Fund Trader

Quote of the Day - August 6, 2021

Tech Letter

“Desperation sometimes drives innovation.” – Said CEO of Uber Dara Khosrowshahi

https://www.madhedgefundtrader.com/wp-content/uploads/2019/03/dara.png 410 318 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-08-06 15:00:052021-08-06 16:11:48Quote of the Day - August 6, 2021
Mad Hedge Fund Trader

August 6, 2021

Diary, Newsletter, Summary

Global Market Comments
August 6, 2021
Fiat Lux

Featured Trade:

(MAD HEDGE 2021 H1 TRADE ANALYSIS)
($INDU), (TLT), (GLD), (XME), (DAL), (FCX), (TSLA)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-08-06 11:04:262021-08-06 11:29:53August 6, 2021
Mad Hedge Fund Trader

Mad Hedge 2021 H1 Trade Analysis

Diary, Newsletter, Research

I finally managed to carve out a few hours to analyze my 2021 H1 trades, and what a year it’s been!

From January 1 to June 30, the Mad Hedge Fund Trader sent you 124 trade alerts completing 64 round trips in four asset classes. These generated a profit of 70.59% in six months, more than we made all of last year.

It is the most prolific performance since we launched Mad Hedge Fund Trader 14 years ago.

In my January 6 Mad Hedge Annual Asset Class Review (click here for the link--you must be logged in to the site), I predicted that the Dow Average ($INDU) would rise 30% for the end of the year. This proved immensely valuable.

That view enabled me to go maximum aggressive, full speed ahead, damn the torpedoes. It’s not that I was so certain that the stock market would go ballistic to the upside. But with the Federal Reserve pumping trillions of dollars of quantitative easing into the economy, record deficit spending, and the pandemic coming under control, I was certain that markets would not go down.

So, I looked into my bag of tricks and pulled out a strategy ideal for this scenario, the in-the-money vertical bull call debit spread (click here for the video on how to execute one of these). Such an approach allowed me to make a maximum profit even if the underlying security went up, sideways, or down small. It worked like a charm.

Here are by trades assorted by asset class:

Equities – 44.14%
Bonds – 24.12%
Commodities – 1.52%
Precious Metals – 0.81%

2021 was definitely the year of equities. In fact, the risk/reward for equities was so compelling that it was almost a waste of time to look at anything else. Equity trades accounted for 62.53% of my total profits.

I split my equity selections with my well-known “barbell strategy” with equal allocations split between big technology and domestic recovery stocks. That way, I always had positions that were going up.

Short positions in the bond market (I had only one long trade) accounted for another 34.17% of my performance. This was basically a first-quarter trade where I caught the collapsing bond market by both lapels and shook it for all it was worth, catching a dive from $162 to $132 in the United States Treasury Bond Fund (TLT). I mostly quit bond trading in March, not wanting to visit the trough too many times in an extremely oversold condition. That was a great call.

Commodities delivered another 2.15% of return with a single trade in the SPDR S&P Metals & Mining ETF (XME). I thought exploding economic growth would cause commodity prices to soar, and they did. But there were better plays to be had buying key stocks in the sector directly, such as Freeport McMoRan (FCX).

As an afterthought, I made another 1.15% in precious metals with two trades long gold. I thought gold would go up this year but so far, no luck. The gold (GLD) faded away when US Treasury bonds became the asset class of choice from March onward.

Of 64 round trips, I lost money on only four, giving me a success rate of 93.75%, far and away the best in the industry. One was a short in Tesla (TSLA) in the $800s. It later fell to $550. The next was a long in Tesla. I got stopped out when it fell below $600. That’s OK because I made a 10X return trading Tesla in 2020.

Welcome to show business.

The next hickey came from a long in Microsoft (MSFT) which I got stopped out of. It went straight up afterwards. Then I took a small hit in Delta Airlines (DAL) for the same reason. The higher the market goes, the faster I stop out as part of my risk control discipline.

All in all, it’s been one hell of a year. I cut back my trading dramatically in June and July partly because the market was so incredibly high, but also to give my loyal staff a rest. Imagine working double overtime for a year and a half! How about sending out 13 trade alerts out in one day!

We are now all refreshed and well-rested ready to take on all comers in H2. The harder I work, the luckier I get. It really is true.

As I tell my beginning traders, work in, money out.

To download the entire 2021 H1 trade history, please click here.

Good Luck and Good Trading
John Thomas
CEO & Publisher
The Diary of a Mad Hedge Fund Trader

 

Capturing Peak Profits

 

 

 

 

 

 

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-08-06 11:02:572021-08-06 11:29:22Mad Hedge 2021 H1 Trade Analysis
Mad Hedge Fund Trader

August 5, 2021 - Quote of the Day

Diary, Newsletter, Quote of the Day

“And when he goes to Heaven to Saint Peter, he will tell, “Another Marine reporting sir, I’ve served my time in Hell,” inscribed on a wooden cross at a grave on Guadalcanal.

 

 

https://www.madhedgefundtrader.com/wp-content/uploads/2019/12/trends.png 286 262 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-08-06 11:00:282021-08-06 11:26:59August 5, 2021 - Quote of the Day
Mad Hedge Fund Trader

Trade Alert - (SPY) August 6, 2021 - SELL-STOP LOSS

Trade Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-08-06 10:45:352021-08-06 10:45:35Trade Alert - (SPY) August 6, 2021 - SELL-STOP LOSS
Mad Hedge Fund Trader

August 5, 2021

Biotech Letter

 

Mad Hedge Biotech & Healthcare Letter
August 5, 2021
Fiat Lux

FEATURED TRADE:

(LET THE BIOTECH BUYOUTS BEGIN)
(TBIO), (SNY), (MRNA), (PFE), (BNTX), (ARCT), (GSK), (JNJ), (MRK), (BLUE), (CVAC)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-08-05 16:02:482021-08-05 16:26:01August 5, 2021
Mad Hedge Fund Trader

Let the Biotech Buyouts Begin

Biotech Letter

One of my predictions for this year just came true: the biotechnology buyouts have begun.

In my letter last January, I forecasted that the growing popularity of the mRNA technology courtesy of the COVID-19 vaccines from Moderna (MRNA) and Pfizer (PFE / BioNTech (BNTX) would trigger acquisitions of smaller biotechnology companies this year.

I predicted that bigger players in the healthcare industry would scoop up smaller players to stake a claim in this quickly growing space.

Topping our list of buyout candidates is Translate Bio (TBIO)—the very same company hogging headlines in the past days following its $3.2 billion acquisition by Sanofi (SNY).

The all-cash deal values each TBIO share at $38, representing a premium of over 30% above the stock’s price. If all goes well, the deal should be completed by the third quarter of 2021.

This is one of the first major moves by Sanofi following the healthcare giant’s recent pivot into vaccines.

However, this isn’t the first time Sanofi and TBIO worked together.

The two companies have actually started collaborating back in 2018, working on a potential mRNA-based flu vaccine—a project that has Sanofi and TBIO ahead of the pack, with BioNTech and Arcturus Therapeutics Inc. (ARCT) trailing behind.

Sanofi and TBIO’s mRNA seasonal flu vaccine candidate is expected to commence with Phase 1 results expected to be out by the fourth quarter of this year.

Considering that Sanofi is one of the leading vaccine makers in the world with roughly $3 billion in sales in flu vaccines alone in 2020, it won’t come as a surprise if their candidate breezes through the trials. 

Even prior to this acquisition, Translate Bio has been working on using its mRNA platform to develop vaccines and treatments for a broad range of diseases like liver and pulmonary ailments.

So far, its novel pipeline has 2 clinical-stage programs along with 7 pre-clinical work covering direct therapeutics and vaccines.

One of its lead candidates is MRT5005, which is an mRNA-based therapy for cystic fibrosis (CF).

This is a groundbreaking treatment because it takes advantage of mRNA’s capability to deliver proteins to lung cells. It’s also extremely non-invasive, as patients can simply inhale the mRNA drug into their bodies.

Other than helping with the treatment of CF, this inhalation delivery system can also open avenues for other pulmonary targets.

Most importantly, TBIO’s MRT5005 doesn’t only offer treatments. It actually is a cure for CF.

TBIO’s work on CF treatment is extremely important. This disease is terrible, recording a median age of death among patients in the US as 30.6 years old. In this country alone, over 30,000 people suffer from the condition, and more than 70,000 are recorded worldwide—and the numbers continue to climb each year.  

In terms of the CF market, the global demand for treatments for this disease is expected to reach $16.3 billion by 2026, hitting roughly 16.8% in CAGR over the years.

With the acquisition of Translate Bio, Sanofi plows ahead of its competitors in the space, including Pfizer, GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), and Merck (MRK), as the sole Big Pharma company with a wholly-owned in-house mRNA platform.

This is on top of Sanofi’s recent $470 buyout of another mRNA company, Tidal Therapeutics, to bolster its immuno-oncology and inflammatory diseases segments.

Apart from its aggressive buyout strategy, Sanofi also announced its plan to allocate roughly $476 million annually to a “vaccines mRNA Center of Excellence” with the goal of queuing at least six mRNA-based candidates in clinical trials by 2025.

Allotting $476 million to this plan is a telling move on the company’s future direction, as it comprises a substantial fraction of Sanofi’s $6.5 billion overall R&D budget.

These moves strongly signal that Sanofi’s going all-in on the mRNA platform, which could obviously pose a challenge to the likes of Moderna and, of course, BioNTech.

With smaller cap companies like bluebird Bio (BLUE) and CureVac (CVAC) still up for grabs, it’s only a matter of time before another big company decides to follow suit.

 

translate bio

 

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-08-05 16:00:532021-08-10 21:28:57Let the Biotech Buyouts Begin
Mad Hedge Fund Trader

Trade Alert - (ROKU) August 5, 2021 - BUY

Tech Alert

When John identifies a strategic exit point, he will send you an alert with specific trade information as to what security to sell, when to sell it, and at what price. Most often, it will be to TAKE PROFITS, but, on rare occasions, it will be to exercise a STOP LOSS at a predetermined price to adhere to strict risk management discipline. Read more

https://www.madhedgefundtrader.com/wp-content/uploads/2016/02/Alert-e1457452190575.jpg 135 150 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-08-05 13:12:272021-08-05 13:12:27Trade Alert - (ROKU) August 5, 2021 - BUY
Mad Hedge Fund Trader

August 5, 2021

Diary, Newsletter, Summary

Global Market Comments
August 5, 2021
Fiat Lux

Featured Trade:

(THE NEW AI BOOK THAT INVESTORS ARE SCRAMBLING FOR),
(GOOG), (FB), (AMZN), MSFT), (BABA), (BIDU),
(TENCENT), (TSLA), (NVDA), (AMD), (MU), (LRCX)

https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png 0 0 Mad Hedge Fund Trader https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png Mad Hedge Fund Trader2021-08-05 09:04:412021-08-05 16:00:36August 5, 2021
Page 10 of 12«‹89101112›»

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
Scroll to top